Infectious Disease

Anaphylaxis was not often reported with the primary four million doses of the Moderna vaccine

January 22, 2021

1 min read

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Anaphylaxis was rarely reported among the first 4 million recipients of the second COVID-19 vaccine approved for use in the United States. CDC and FDA reported in MMWR.

According to the report, more than 1,200 adverse events were reported between December 21 and January 10 after being vaccinated with Moderna’s COVID-19 vaccine. Of these, 108 were classified as allergic reactions and 10 were confirmed as cases of anaphylaxis – the equivalent of 2.5 cases per million doses administered – according to data compiled from the Vaccine Adverse Event Reporting System.

Covid vaccination

The rate of anaphylaxis among those vaccinated with the Moderna COVID-19 vaccine is 2.5 cases per million doses administered.
Photo credit: Adobe Stock

The report stated that nine cases of anaphylaxis were reported in people with a documented history of allergies or allergic reactions, including five with a history of anaphylaxis. According to the report, the mean time between receiving the vaccine and showing symptoms was 7.5 minutes, but was between 1 and 45 minutes. Of the eight people with available follow-up information, all are said to have recovered or been sent home.

“Because of this early monitoring, anaphylaxis appears to be a rare occurrence after receiving the Moderna COVID-19 vaccine. However, comparing the risk of anaphylaxis with the risk of non-COVID-19 vaccines is currently limited by the limited data available at the start of the COVID-19 vaccination program, ”write members of the CDC COVID-19 Response Team and the FDA im Report.

Moderna’s vaccine was the second emergency-approved COVID-19 vaccine in the United States. Earlier this month, the CDC and FDA reported that the first vaccine developed by Pfizer and BioNTech COVID-19 was also rarely associated with anaphylaxis with 21 cases confirmed among the first 1,893,360 recipients of the vaccine.

Back then, Nancy E. Messonnier, MD, The director of the CDC’s National Center for Immunization and Respiratory Diseases said the number “may seem high, but this is still a rare finding.”

As a precaution, researchers said vaccination sites should be equipped to treat these reactions should they occur, and the CDC has released updated preliminary clinical considerations to reflect this.

“Sites receiving COVID-19 vaccines should follow CDC guidelines, including screening recipients for contraindications and precautions, providing necessary supplies and staff to treat anaphylaxis, implementing recommended post-vaccination observation periods and prompt treatment of suspected anaphylaxis with intramuscular adrenaline injection. ” Authors of the new report posted.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles